3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Virus Diseases
1
Tumor Virus Infections
1
Squamous Cell Carcinoma of Head and Neck
1
Pharyngeal Diseases
1
Papillomavirus Infections
1
Otorhinolaryngologic Neoplasms
1
Otorhinolaryngologic Diseases
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Head and Neck Neoplasms
1
DNA Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
pembrolizumab
224
Cyclophosphamide
192
Radiotherapy
183
Nivolumab
180
Carboplatin
153
Cisplatin
114
Paclitaxel
112
Dexamethasone
110
Radiosurgery
104
Magnetic Resonance Spectroscopy
97
Surveys and Questionnaires
91
Ipilimumab
81
Doxorubicin
79
Lenalidomide
76
durvalumab
75
Rituximab
75
atezolizumab
72
Radiation
72
venetoclax
69
fludarabine
68
Standard of Care
68
Gemcitabine
68
Specimen Handling
65
Etoposide
64
Capecitabine
64
Bevacizumab
62
Oxaliplatin
59
Docetaxel
58
Biopsy
58
Radiotherapy, Intensity-Modulated
56
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
OTHER
×
Nimorazole
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled